Johnson & Johnson logo
Johnson & Johnson (JNJ)
Compare

Johnson & Johnson (JNJ) PE Ratio: 27.79

Is Johnson & Johnson’s P/E ratio high or low?

Johnson & Johnson's P/E ratio of 27.79 is 27% above its 5-year average of 21.89, around the middle of its 5-year range (9.51–36.50).

As of Thursday, June 11, 2026. 33.90% above its 12-month average of 20.76.

PE Ratio (27.79) = Close Price ($238.49) / Diluted TTM EPS ($8.58)

JNJ PE Ratio Chart

JNJ PE Ratio
27.79+60.91% 1Y
Zoom

JNJ Average PE Ratio Chart

JNJ Current vs Average PE Ratio Chart

JNJ PE Ratio Metrics

PE RATIO

27.79

PE RATIO AVG TTM

20.76

PE RATIO AVG 3Y

19.80

PE RATIO AVG 5Y

21.89

PE RATIO AVG 10Y

50.87

PE RATIO AVG 15Y

40.29

PE RATIO AVG 20Y

34.00

CURRENT VS TTM AVG

+33.90%

CURRENT VS 3Y AVG

+40.39%

CURRENT VS 5Y AVG

+26.98%

CURRENT VS 10Y AVG

-45.37%

CURRENT VS 15Y AVG

-31.02%

CURRENT VS 20Y AVG

-18.28%

JNJ Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
Johnson & Johnson (JNJ)$577.73B27.7920.7619.8021.89
Pfizer Inc. (PFE)$149.61B20.0616.3722.3918.18
Merck & Co., Inc. (MRK)$298.23B34.0215.8894.3865.32
AbbVie Inc. (ABBV)$399.86B110.93116.4475.5855.76
Eli Lilly and Company (LLY)$1.10T41.3048.8782.7268.86
Bristol-Myers Squibb Company (BMY)$116.13B15.9817.6216.3419.36

P/E vs. its own history

At 27.8, P/E is richer than usual, sitting higher than 90% of its 20-year history.

20-year low

9.5

median

19.8

20-year high

348.7

cheaperricher

P/E Comparison

Trailing P/E

27.8

Forward P/E

18.7

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$238.49

÷

Forward EPS (Est.)

$12.77

=

Forward P/E

18.68

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Johnson & Johnson PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Johnson & Johnson PE Ratio FAQ

What is the P/E ratio for Johnson & Johnson (JNJ)?
The P/E ratio for JNJ stock is 27.79.
Is Johnson & Johnson's P/E ratio high or low?
Johnson & Johnson's P/E ratio of 27.79 is 27% above its 5-year average of 21.89, around the middle of its 5-year range (9.51–36.50).
What is the TTM average P/E ratio for Johnson & Johnson (JNJ)?
The TTM average P/E ratio for JNJ stock is 20.76.
What is the 3Y average P/E ratio for Johnson & Johnson (JNJ)?
The 3Y average P/E ratio for JNJ stock is 19.80.
What is the 5Y average P/E ratio for Johnson & Johnson (JNJ)?
The 5Y average P/E ratio for JNJ stock is 21.89.
What is the 10Y average P/E ratio for Johnson & Johnson (JNJ)?
The 10Y average P/E ratio for JNJ stock is 50.87.
What is the 15Y average P/E ratio for Johnson & Johnson (JNJ)?
The 15Y average P/E ratio for JNJ stock is 40.29.
What is the 20Y average P/E ratio for Johnson & Johnson (JNJ)?
The 20Y average P/E ratio for JNJ stock is 34.00.

Johnson & Johnson PE Ratio History

DATEPE RATIO
2026-06-1127.79
2026-06-1027.57
2026-06-0927.40
2026-06-0826.84
2026-06-0526.91
2026-06-0426.38
2026-06-0325.81
2026-06-0225.77
2026-06-0125.84
2026-05-2926.05
2026-05-2826.68
2026-05-2726.74
2026-05-2626.61
2026-05-2227.09
2026-05-2126.79
2026-05-2026.51
2026-05-1926.59
2026-05-1826.46
2026-05-1526.21
2026-05-1426.68
2026-05-1326.64
2026-05-1225.93
2026-05-1125.60
2026-05-0825.59
2026-05-0725.72
2026-05-0625.97
2026-05-0526.08
2026-05-0425.92
2026-05-0126.26
2026-04-3026.57
2026-04-2926.28
2026-04-2826.33
2026-04-2726.05
2026-04-2426.30
2026-04-2326.66
2026-04-2226.14
2026-04-2120.47
2026-04-2020.88
2026-04-1721.19
2026-04-1621.23
2026-04-1521.60
2026-04-1421.73
2026-04-1321.53
2026-04-1021.58
2026-04-0921.84
2026-04-0821.84
2026-04-0721.58
2026-04-0621.81
2026-04-0221.99
2026-04-0122.09
2026-03-3122.12
2026-03-3021.94
2026-03-2721.76
2026-03-2621.65
2026-03-2521.71
2026-03-2421.29
2026-03-2321.30
2026-03-2021.30
2026-03-1921.50
2026-03-1821.47
2026-03-1721.55
2026-03-1622.01
2026-03-1321.86
2026-03-1221.90
2026-03-1121.99
2026-03-1022.06
2026-03-0921.95
2026-03-0621.76
2026-03-0521.69
2026-03-0422.20
2026-03-0322.33
2026-03-0222.49
2026-02-2722.48
2026-02-2622.03
2026-02-2522.19
2026-02-2422.29
2026-02-2322.25
2026-02-2021.94
2026-02-1922.34
2026-02-1822.17
2026-02-1722.02
2026-02-1322.03
2026-02-1222.13
2026-02-1121.80
2026-02-1023.01
2026-02-0923.03
2026-02-0623.17
2026-02-0522.95
2026-02-0422.63
2026-02-0322.50
2026-02-0222.27
2026-01-3021.94
2026-01-2921.94
2026-01-2821.98
2026-01-2721.66
2026-01-2621.38
2026-01-2321.25
2026-01-2221.09
2026-01-2121.04
2026-01-2021.06
2026-01-1621.11
2026-01-1521.19
2026-01-1421.10
2026-01-1320.62
2026-01-1220.24
2026-01-0919.73
2026-01-0819.86
2026-01-0720.03
2026-01-0619.77
2026-01-0519.72
2026-01-0220.01
2025-12-3119.98
2025-12-3019.97
2025-12-2920.03
2025-12-2620.04
2025-12-2420.06
2025-12-2319.86
2025-12-2220.01
2025-12-1919.92
2025-12-1820.11
2025-12-1720.30
2025-12-1620.20
2025-12-1520.67
2025-12-1220.42
2025-12-1120.27
2025-12-1019.94
2025-12-0919.30
2025-12-0819.46
2025-12-0519.49
2025-12-0419.54
2025-12-0319.82
2025-12-0219.83
2025-12-0119.82
2025-11-2819.97
2025-11-2620.03
2025-11-2519.95
2025-11-2419.89
2025-11-2119.68
2025-11-2019.60
2025-11-1919.55
2025-11-1819.31
2025-11-1719.26
2025-11-1418.91
2025-11-1318.85
2025-11-1218.76
2025-11-1118.71
2025-11-1018.19
2025-11-0718.01
2025-11-0618.05
2025-11-0517.95
2025-11-0418.04
2025-11-0317.98
2025-10-3118.23
2025-10-3018.25
2025-10-2918.01
2025-10-2818.04
2025-10-2718.37
2025-10-2418.38
2025-10-2318.58
2025-10-2218.62
2025-10-2120.52
2025-10-2020.72
2025-10-1720.67
2025-10-1620.55
2025-10-1520.45
2025-10-1420.41
2025-10-1320.42
2025-10-1020.40
2025-10-0920.44
2025-10-0820.29
2025-10-0720.20
2025-10-0620.12
2025-10-0320.18
2025-10-0219.89
2025-10-0119.90
2025-09-3019.83
2025-09-2919.42
2025-09-2619.22
2025-09-2519.01
2025-09-2418.90
2025-09-2318.89
2025-09-2218.63
2025-09-1918.84
2025-09-1818.63
2025-09-1718.95
2025-09-1618.87
2025-09-1518.97
2025-09-1219.04
2025-09-1119.09
2025-09-1018.80
2025-09-0918.93
2025-09-0819.05
2025-09-0519.08
2025-09-0419.12
2025-09-0319.04
2025-09-0219.04
2025-08-2918.95
2025-08-2818.76
2025-08-2718.91
2025-08-2618.88
2025-08-2519.08
2025-08-2219.18
2025-08-2119.14
2025-08-2019.13
2025-08-1919.02
2025-08-1818.85
2025-08-1518.89
2025-08-1418.69
2025-08-1318.65
2025-08-1218.48
2025-08-1118.59
2025-08-0818.54
2025-08-0718.35
2025-08-0618.24
2025-08-0518.26
2025-08-0418.29
2025-08-0117.90
2025-07-3117.62
2025-07-3017.89
2025-07-2917.98
2025-07-2817.78
2025-07-2518.00
2025-07-2418.13
2025-07-2318.81
2025-07-2218.68
2025-07-2118.28
2025-07-1818.21
2025-07-1718.13
2025-07-1618.33
2025-07-1517.26
2025-07-1417.44
2025-07-1117.45
2025-07-1017.54
2025-07-0917.38
2025-07-0817.33
2025-07-0717.27
2025-07-0317.35
2025-07-0217.30
2025-07-0117.34
2025-06-3016.99
2025-06-2716.95
2025-06-2616.91
2025-06-2516.94
2025-06-2416.93
2025-06-2316.83
2025-06-2016.66
2025-06-1816.77
2025-06-1716.95
2025-06-1617.27
2025-06-1317.47
2025-06-1217.43
2025-06-1117.27
2025-06-1017.40
2025-06-0917.27
2025-06-0617.24
2025-06-0517.09
2025-06-0417.04
2025-06-0317.18
2025-06-0217.29
2025-05-3017.26

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

About Johnson & Johnson

Johnson & Johnson (JNJ) operates globally, engaging in the research, development, production, and distribution of a diverse range of healthcare products. In a pivotal strategic move in 2023, the company divested its Consumer Health division, establishing it as the independent entity Kenvue Inc. This separation was implemented to allow J&J to sharpen its focus on higher-growth, innovation-led areas. Consequently, well-known consumer brands like TYLENOL, LISTERINE, and BAND-AID are now part of Kenvue's portfolio. Johnson & Johnson's current operations are centered around two primary divisions: Innovative Medicine and MedTech. The Innovative Medicine segment, formerly known as Pharmaceuticals, specializes in prescription drugs designed to treat complex ailments such as rheumatoid arthritis, various forms of cancer, HIV/AIDS, and neurodegenerative disorders. Its MedTech division, encompassing Medical Devices, delivers cutting-edge technological solutions, including electrophysiology equipment, neurovascular care products, orthopaedic implants for hips, knees, and spine, advanced surgical technologies, and ACUVUE brand disposable contact lenses. These two streamlined segments primarily cater to a client base comprising hospitals, medical professionals, wholesale distributors, and retail outlets. From its headquarters in New Brunswick, New Jersey, Johnson & Johnson continues to uphold its enduring mission of advancing human health, a commitment it has maintained since its founding in 1886.

New Brunswick, NJ
138,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato